Viral Vector Manufacturing Facility

Sydney Children’s Hospitals Network (SCHN) will be home to the first stage of the Viral Vector Manufacturing Facility.
It is one of the only viral vector manufacturing facilities in the country and will be managed by SCHN in association with the Office for Health and Medical Research and Health Infrastructure.
The facility will produce clinical grade viral vectors, key components of gene and cell therapies, giving patients with genetic diseases and cancers across Australia faster access to groundbreaking trial therapies.  
The second stage of the viral vector manufacturing will be developed at Westmead over the next 2 years.  

The big picture

NSW has invested $25 million in a clinical grade viral vector manufacturing facility at the Westmead Health and Innovation District.
This investment is critical to strengthening NSW’s capacity to futureproof our vaccine supply chain and enable NSW to combat future health challenges from pandemics to cancer and genetic diseases.
Health Infrastructure is proud to support the growth of our research and advanced biomanufacturing industry, placing NSW at the forefront of technology and innovation that will change people’s lives for the better.

See the latest video from Investment NSW